A Thr357 to Ser Polymorphism in Homozygous and Compound Heterozygous Subjects Causes Absent or Reduced P2X7 Function and Impairs ATP-induced Mycobacterial Killing by Macrophages
Overview
Authors
Affiliations
The P2X(7) receptor is a ligand-gated cation channel that is highly expressed on mononuclear leukocytes and that mediates ATP-induced apoptosis and killing of intracellular pathogens. There is a wide variation in P2X(7) receptor function between subjects, explained in part by four loss-of-function polymorphisms (R307Q, E496A, I568N, and a 5'-intronic splice site polymorphism), as well as rare mutations. In this study, we report the allele frequencies of 11 non-synonymous P2X(7) polymorphisms and describe a fifth loss-of-function polymorphism in the gene (1096C --> G), which changes Thr(357) to Ser (T357S) with an allele frequency of 0.08 in the Caucasian population. P2X(7) function was measured by ATP-induced ethidium(+) influx into peripheral blood lymphocytes and monocytes and, when compared with wild-type subjects, was reduced to 10-65% in heterozygotes, 1-18% in homozygotes, and 0-10% in compound heterozygotes carrying T357S and a second loss-of-function polymorphism. Overexpression of the T357S mutant P2X(7) in either HEK-293 cells or Xenopus oocytes gave P2X(7) function of approximately 50% that of wild-type constructs. Differentiation of monocytes to macrophages, which also up-regulates P2X(7), restored P2X(7) function to near normal in cells heterozygous for T357S and to a value 50-65% of wild-type in cells homozygous for T357S or compound heterozygous for T357S/E496A. However, macrophages from subjects that are compound heterozygous for either T357S/R307Q or T357S/stop codon had near-to-absent P2X(7) function. These functional deficits induced by T357S were paralleled by impaired ATP-induced apoptosis and mycobacteria killing in macrophages from these subjects. Lymphocytes, monocytes, and macrophages from subjects homozygous for T357S or compound heterozygous for T357S and a second loss-of-function allele have reduced or absent P2X(7) receptor function.
Guggemos J, Fuller S, Skarratt K, Mayer B, Schneider E Front Immunol. 2024; 15:1352789.
PMID: 38966639 PMC: 11222724. DOI: 10.3389/fimmu.2024.1352789.
Sharafeldin N, Zhou L, Singh P, Crossman D, Wang X, Hageman L JACC CardioOncol. 2024; 5(6):807-818.
PMID: 38205005 PMC: 10774788. DOI: 10.1016/j.jaccao.2023.06.007.
Guerini F, Agliardi C, Bolognesi E, Zanzottera M, Caputo D, Pasanisi M Int J Mol Sci. 2022; 23(23).
PMID: 36499708 PMC: 9736555. DOI: 10.3390/ijms232315381.
Schafer W, Stahler T, Pinto Espinoza C, Danquah W, Knop J, Rissiek B Front Pharmacol. 2022; 13:1033135.
PMID: 36467077 PMC: 9715982. DOI: 10.3389/fphar.2022.1033135.
Identification of Leukocyte Surface P2X7 as a Biomarker Associated with Alzheimer's Disease.
Li Y, Huang X, Fowler C, Lim Y, Laws S, Faux N Int J Mol Sci. 2022; 23(14).
PMID: 35887215 PMC: 9322488. DOI: 10.3390/ijms23147867.